Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, Japan, March 16, 2009 – Astellas Pharma Inc. (“Astellas”) today announced that it will terminate its $16.00 per share offer for CV Therapeutics, Inc. (Nasdaq: CVTX) and will not...
Tokyo, Japan, March 6, 2009 – Astellas Pharma Inc. today announced that its wholly owned subsidiary, Astellas US Holding, Inc., will nominate two directors for election to the Board of Directors...
Japan, March 3, 2009 - Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter “Astellas”) today announced that Astellas has terminated the License...
TOKYO, JAPAN and SANTA CLARA, CA- March 2, 2009 - Astellas Pharma Inc. (Astellas) and XenoPort, Inc. (NASDAQ: XNPT) today announced preliminary top-line results from a Phase 2 clinical trial of...
Tokyo, Japan, February 27, 2009 – Astellas US Holding, Inc., a wholly owned subsidiary of Astellas Pharma Inc., today announced that it has filed a lawsuit in the Delaware Chancery Court against...
Tokyo, Japan, February 27, 2009 – Astellas Pharma Inc. (“Astellas”) today announced that its indirect subsidiary, Sturgeon Acquisition, Inc., has commenced a cash tender offer for all...
Tokyo, Japan, February 23, 2009 – Astellas Pharma Inc. (“Astellas”) today commented on CV Therapeutics, Inc’s. (Nasdaq: CVTX) announcement that its Board of Directors has rejected...
Japan, February 3, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; president and CEO: Masafumi Nogimori) announced today that it will implement changes to its global development...
Tokyo, Japan, January 27, 2009 – Astellas Pharma Inc. (“Astellas”) today announced that it has submitted a proposal to the Board of Directors of CV Therapeutics, Inc. (Nasdaq: CVTX) to...
Japan, January 21, 2009 - Ono Pharmaceutical Co., Ltd. (“Ono”; headquarters: Osaka; President and Representative Director: Gyo Sagara) and Astellas Pharma Inc. (“Astellas”; headquarters:...
Follow us
